95% of Oregon Psilocybin Study Participants Saw Improvements in Depression, PTSD
Impact on your practice
While this research is promising for future treatment options, it has limited immediate impact on current therapist practice, billing, or licensing. Psilocybin-assisted therapy remains illegal federally and is not yet a billable service for most therapists. This is primarily relevant for researchers and future-focused practitioners monitoring emerging modalities.
Key facts
Oregon psilocybin study shows 92.2% of 350 participants reported improvements in depression, anxiety, and mental wellbeing
Only 1.2% experienced adverse behavioral reactions requiring medical attention
Oregon legalized psilocybin in 2020 under a recreational (not medical) model, requiring clinical safety research
Study was conducted in controlled environment with trained facilitators overseeing safety protocols
Therapy Companion analysis
This Oregon research has minimal direct impact on your current practice, billing, or licensing, but signals a trajectory worth monitoring. Psilocybin-assisted therapy remains a Schedule I controlled substance federally, meaning you cannot bill for it, refer patients to it through insurance, or incorporate it into your clinical workflow today. Even in Oregon, where supervised psilocybin sessions are legal, the service operates outside traditional mental health reimbursement—patients pay $850–$3,000 out-of-pocket per session, and there is no insurance coverage pathway yet. Your role as a therapist in this emerging space remains limited to patient education and potential future collaboration if FDA approval occurs and your state develops a regulated medical model (unlike Oregon's current recreational framework). The real practice implications emerge only if and when psilocybin receives FDA approval for a specific indication (depression, PTSD, substance use disorder), at which point reimbursement, scope-of-practice questions, and training requirements will reshape the landscape. Until then, this research validates efficacy but does not create billable services, prior authorization requirements, or licensing changes for your credential.
Background
Oregon's 2020 legalization of psilocybin created the first state-regulated framework for supervised psychedelic use in the United States, but it followed a recreational model rather than a medical one—a critical distinction. This meant Oregon had to build clinical safety evidence from scratch to justify therapeutic use outside a formal FDA-approved medical indication. The Oregon Health and Science University study represents that foundational safety work: demonstrating that 92.2% of 350 participants reported improvements in depression, anxiety, and mental wellbeing, with only 1.2% experiencing adverse behavioral reactions requiring medical attention. Nationally, psilocybin and MDMA are competing for FDA breakthrough therapy designation, with both showing promise in clinical trials for treatment-resistant depression and PTSD. However, federal approval remains pending, and the path to insurance coverage and mainstream clinical integration is uncertain. The study's findings are significant for researchers and policy advocates but do not yet translate into a billable modality or scope-of-practice expansion for licensed therapists.
What you should do
Monitor FDA breakthrough therapy designations for psilocybin and MDMA; subscribe to FDA announcements or join professional association policy committees to track when (if) these substances move toward medical approval, which would trigger scope-of-practice and training discussions for your credential.
If you practice in Oregon or another state considering psilocybin legalization, familiarize yourself with the regulatory framework (recreational vs. medical model) and clarify whether your license permits you to serve as a session facilitator, co-facilitator, or referring clinician; do not assume your credential qualifies you without explicit state guidance.
Document your current clinical protocols for patients asking about psilocybin or other psychedelics; establish a clear referral and informed-consent process that acknowledges federal illegality, lack of insurance coverage, and the distinction between research settings and unregulated providers.
Avoid marketing or implying that psilocybin-assisted therapy is available through your practice unless you are explicitly licensed and trained as a facilitator in a state with legal, regulated access; liability and scope-of-practice violations are significant risks.
Engage with your state licensing board or professional association to understand how psilocybin training, if it becomes available, would be credentialed and whether it would require additional certification, continuing education, or scope-of-practice amendments to your license.
Notable excerpts
"Just because something isn't a medical model doesn't mean you can't have mental health benefits. Still, people [with] serious mental health or medical conditions should talk with their healthcare providers before seeking services." – Dr. Todd Korthuis, lead researcher, Oregon Health and Science University.
A legal, supervised, single psilocybin dosing session in Oregon currently costs between $850 and $3,000 per person out-of-pocket, with no insurance coverage pathway established.
States affected
Policy changes drive denial patterns
Therapy Companion tracks both: the policy shifts on this page and the denial patterns hitting your claims.
Related policy changes
[MA] H4895: Expanding access to mental health services
This bill aims to expand mental health service access in Massachusetts and has cleared committee with a favorable recommendation. Depending on final language, it could affect reimbursement rates, telehealth authorization, or insurance coverage requirements.
[TN] SB1248: AN ACT to amend Tennessee Code Annotated, Title 4; Title 8; Title 33; Title 39; Title 49; Title 53; Title 56; Title 63; Title 68 and Title 71, relative to mental health.
This comprehensive TN mental health bill touches multiple code sections and could affect licensure, scope of practice, insurance requirements, and workforce regulations. Therapists should monitor its progress closely as it moves through committee.
Advancing the Future of Behavioral Health Data Exchange
This policy direction addresses a critical pain point for therapists: the lack of integrated health data exchange with primary care and medical providers. Improved interoperability could reduce documentation burden, improve care coordination, and reduce liability from medication interactions or missed diagnoses. However, it may also increase compliance requirements and data security obligations.
Opinion: MAHA is rewriting the vocabulary of American mental health care
Federal deprescribing initiatives create new clinical and billing opportunities for therapists while potentially pressuring prescribing practices. Therapists should understand the evidence, reimbursement rules, and ethical considerations around medication tapering to protect clients and navigate changing clinical norms.